, , , , , ,

Diabetes Drug Invokana Linked to Cardiovascular Risks and Diabetic Ketoacidosis

Invokana (canagliflozin) was approved by the FDA in March 2013 to treat patients who suffer from Type 2 diabetes. It is prescribed to improve glycemic control and to lower blood sugar in adults with Type 2 diabetes mellitus. Diabetes causes…